Header Logo

Connection

MALCOLM BRENNER to Child, Preschool

Back to Details
This is a "connection" page, showing publications MALCOLM BRENNER has written about Child, Preschool.
MALCOLM BRENNER
Connection Strength
0.689
Child, Preschool
  1. CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. Mol Ther. 2017 09 06; 25(9):2214-2224.
    View in: PubMed
    Score: 0.045
  2. Severe congenital malformations, family functioning and parents' separation/divorce: a longitudinal study. Child Care Health Dev. 2016 Jan; 42(1):16-24.
    View in: PubMed
    Score: 0.039
  3. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.039
  4. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 Nov 03; 365(18):1673-83.
    View in: PubMed
    Score: 0.030
  5. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 Dec 01; 118(23):6050-6.
    View in: PubMed
    Score: 0.030
  6. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008 Nov; 14(11):1264-70.
    View in: PubMed
    Score: 0.025
  7. Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation. Blood. 2006 Sep 15; 108(6):1797-808.
    View in: PubMed
    Score: 0.021
  8. A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28; 101(39):14228-33.
    View in: PubMed
    Score: 0.019
  9. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors. J Clin Oncol. 2024 Aug 10; 42(23):2769-2779.
    View in: PubMed
    Score: 0.018
  10. Cord blood transplantation for nonmalignant disorders: early functional immunity and high survival. Blood Adv. 2023 05 09; 7(9):1823-1830.
    View in: PubMed
    Score: 0.017
  11. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet. 2001 Jan; 27(1):117-20.
    View in: PubMed
    Score: 0.014
  12. Selection of human antitumor single-chain Fv antibodies from the B-cell repertoire of patients immunized against autologous neuroblastoma. Med Pediatr Oncol. 2000 Dec; 35(6):692-5.
    View in: PubMed
    Score: 0.014
  13. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector. Hum Gene Ther. 2000 Jul 01; 11(10):1477-88.
    View in: PubMed
    Score: 0.014
  14. T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor-Expressing T Cells. Clin Cancer Res. 2019 12 15; 25(24):7340-7350.
    View in: PubMed
    Score: 0.013
  15. Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients. Blood Adv. 2019 09 24; 3(18):2689-2695.
    View in: PubMed
    Score: 0.013
  16. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med. 1999 Mar; 5(3):309-13.
    View in: PubMed
    Score: 0.013
  17. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation. Blood. 2018 11 29; 132(22):2351-2361.
    View in: PubMed
    Score: 0.012
  18. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998 Sep 15; 92(6):1941-9.
    View in: PubMed
    Score: 0.012
  19. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Hum Gene Ther. 1998 Jun 10; 9(9):1303-11.
    View in: PubMed
    Score: 0.012
  20. Current Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphocytic Leukemia: Success, Failure and Future Perspectives-A Single-Center Experience, 2008 to 2016. Biol Blood Marrow Transplant. 2018 07; 24(7):1424-1431.
    View in: PubMed
    Score: 0.012
  21. Outcomes after Allogeneic Transplant in Patients with Wiskott-Aldrich Syndrome. Biol Blood Marrow Transplant. 2018 03; 24(3):537-541.
    View in: PubMed
    Score: 0.012
  22. Autologous bone-marrow transplantation in childhood acute lymphoblastic leukaemia. Lancet. 1995 Sep 30; 346(8979):856-7.
    View in: PubMed
    Score: 0.010
  23. Outcomes after Second Hematopoietic Stem Cell Transplantations in Pediatric Patients with Relapsed Hematological Malignancies. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1266-72.
    View in: PubMed
    Score: 0.010
  24. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood. 1994 Jul 15; 84(2):380-3.
    View in: PubMed
    Score: 0.009
  25. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci Transl Med. 2014 Jun 25; 6(242):242ra83.
    View in: PubMed
    Score: 0.009
  26. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood. 2014 Jun 19; 123(25):3895-905.
    View in: PubMed
    Score: 0.009
  27. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994 Apr; 5(4):481-99.
    View in: PubMed
    Score: 0.009
  28. Gene marking to improve the outcome of autologous bone marrow transplantation. Prog Clin Biol Res. 1994; 389:587-91.
    View in: PubMed
    Score: 0.009
  29. Gene marking to improve the outcome of autologous bone marrow transplantation. J Hematother. 1994; 3(1):33-6.
    View in: PubMed
    Score: 0.009
  30. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet. 1993 Nov 06; 342(8880):1134-7.
    View in: PubMed
    Score: 0.009
  31. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013 Nov; 21(11):2113-21.
    View in: PubMed
    Score: 0.008
  32. Excellent survival after sibling or unrelated donor stem cell transplantation for chronic granulomatous disease. J Allergy Clin Immunol. 2012 Jan; 129(1):176-83.
    View in: PubMed
    Score: 0.008
  33. Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infection. Pediatr Blood Cancer. 2012 Oct; 59(4):758-61.
    View in: PubMed
    Score: 0.008
  34. Highlights of the second international conference on "Immunotherapy in Pediatric Oncology". Pediatr Hematol Oncol. 2011 Sep; 28(6):459-60.
    View in: PubMed
    Score: 0.007
  35. Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantation. Pediatr Blood Cancer. 2011 Jan; 56(1):143-51.
    View in: PubMed
    Score: 0.007
  36. The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant. 2010 Sep; 16(9):1272-81.
    View in: PubMed
    Score: 0.007
  37. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2010 Feb 04; 115(5):925-35.
    View in: PubMed
    Score: 0.007
  38. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study. Lancet. 2009 Sep 12; 374(9693):912-20.
    View in: PubMed
    Score: 0.007
  39. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 05; 114(19):4283-92.
    View in: PubMed
    Score: 0.007
  40. Current role and status of bone marrow transplantation. Br J Hosp Med. 1989 Mar; 41(3):260-5.
    View in: PubMed
    Score: 0.006
  41. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008 Nov-Dec; 31(9):812-9.
    View in: PubMed
    Score: 0.006
  42. Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimen. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1245-52.
    View in: PubMed
    Score: 0.006
  43. Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1298-304.
    View in: PubMed
    Score: 0.006
  44. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant. 2006 Dec; 12(12):1277-84.
    View in: PubMed
    Score: 0.005
  45. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Oct; 12(10):1160-6.
    View in: PubMed
    Score: 0.005
  46. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs). Blood. 2006 Nov 01; 108(9):2942-9.
    View in: PubMed
    Score: 0.005
  47. Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancy. Biol Blood Marrow Transplant. 2003 Apr; 9(4):273-81.
    View in: PubMed
    Score: 0.004
  48. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003 Mar 01; 101(5):1718-26.
    View in: PubMed
    Score: 0.004
  49. Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood. 2002 Dec 01; 100(12):4059-66.
    View in: PubMed
    Score: 0.004
  50. Molecular findings in symptomatic and pre-symptomatic Alexander disease patients. Neurology. 2002 May 28; 58(10):1494-500.
    View in: PubMed
    Score: 0.004
  51. Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals. J Immunol. 2002 Jan 15; 168(2):909-18.
    View in: PubMed
    Score: 0.004
  52. Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation. 2001 Sep 27; 72(6):1078-86.
    View in: PubMed
    Score: 0.004
  53. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001 Aug 15; 98(4):1166-73.
    View in: PubMed
    Score: 0.004
  54. Impact of a multidisciplinary day program on disease and healthcare costs in children and adolescents with severe asthma: a two-year follow-up study. Pediatr Pulmonol. 2001 Mar; 31(3):177-89.
    View in: PubMed
    Score: 0.004
  55. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood. 2000 Feb 15; 95(4):1502-5.
    View in: PubMed
    Score: 0.003
  56. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplant. 1999 Oct; 24(7):735-9.
    View in: PubMed
    Score: 0.003
  57. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998 Sep 01; 92(5):1549-55.
    View in: PubMed
    Score: 0.003
  58. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat Med. 1996 May; 2(5):551-5.
    View in: PubMed
    Score: 0.003
  59. Gamma delta T lymphocyte regeneration after T lymphocyte-depleted bone marrow transplantation from mismatched family members or matched unrelated donors. Bone Marrow Transplant. 1996 Feb; 17(2):243-7.
    View in: PubMed
    Score: 0.003
  60. Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1. Lancet. 1995 Sep 23; 346(8978):805-6.
    View in: PubMed
    Score: 0.002
  61. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther. 1995 Sep; 6(9):1231-55.
    View in: PubMed
    Score: 0.002
  62. Psychological effects of bone marrow transplantation on children and adolescents: preliminary report of a longitudinal study. Bone Marrow Transplant. 1995 Jun; 15(6):829-35.
    View in: PubMed
    Score: 0.002
  63. Production of genetically modified Epstein-Barr virus-specific cytotoxic T cells for adoptive transfer to patients at high risk of EBV-associated lymphoproliferative disease. J Hematother. 1995 Apr; 4(2):73-9.
    View in: PubMed
    Score: 0.002
  64. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995 Jan 07; 345(8941):9-13.
    View in: PubMed
    Score: 0.002
  65. Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol. 1995 Jan; 89(1):98-103.
    View in: PubMed
    Score: 0.002
  66. Donor T cells to treat EBV-associated lymphoma. N Engl J Med. 1994 Sep 08; 331(10):679-80.
    View in: PubMed
    Score: 0.002
  67. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors. Bone Marrow Transplant. 1994 May; 13(5):571-5.
    View in: PubMed
    Score: 0.002
  68. Continuous infusion of interleukin-2 in children with refractory malignancies. Cancer. 1993 Jul 15; 72(2):623-8.
    View in: PubMed
    Score: 0.002
  69. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone Marrow Transplant. 1992 Nov; 10(5):457-62.
    View in: PubMed
    Score: 0.002
  70. Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital. Leukemia. 1992; 6 Suppl 2:39-43.
    View in: PubMed
    Score: 0.002
  71. Titration of IgG antibodies against varicella zoster virus before bone marrow transplantation is not predictive of future zoster. J Med Virol. 1989 Feb; 27(2):117-9.
    View in: PubMed
    Score: 0.002
  72. Haemorrhagic cystitis in bone marrow transplantation patients: possible increased risk associated with prior busulphan therapy. Bone Marrow Transplant. 1987 Apr; 1(4):347-55.
    View in: PubMed
    Score: 0.001
  73. Graft rejection following HLA matched T-lymphocyte depleted bone marrow transplantation. Br J Haematol. 1986 Jun; 63(2):221-30.
    View in: PubMed
    Score: 0.001
  74. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet. 1986 Feb 15; 1(8477):339-43.
    View in: PubMed
    Score: 0.001
  75. Production of leucocyte interferon in vitro in children with recurrent respiratory infections. Lancet. 1984 Jun 02; 1(8388):1247.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.